Tumor Antigen Vaccines
Tumor Antigen Vaccines - Related Videos
04:42
An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
0 Views •
2025
This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...
05:09
Repetitive Tumor Challenge Assay: An In Vitro Culture Assay to Evaluate Chimeric Antigen Receptor (CAR) T Cells for Repetitive Tumor Killing Potential
0 Views •
2025
In this video, we demonstrate the repetitive tumor challenge assay to evaluate the CAR T cells’ repetitive tumor killing potential during high tumor cell loads. Further, the CAR T cells can be analyzed using flow cytometry to determine the different subpopulations of CAR T cells in the sample.
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
0 Views •
Cited by 20 •
2013
The most commonly used method for generating large numbers of autologous dendritic cells (DCs) for use in tumor immunotherapy is described. The method uses IL-4 and GM-CSF to differentiate DCs from monocytes. The immature DCs are stimulated to mature and then loaded with antigens before they are injected back into the patient.
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
0 Views •
Cited by 9 •
2016
In this antigen-driven colitis model, OT-II CD4+ T cells expressing a red fluorescent protein were adoptively transferred into RAG-/- mice that express a green fluorescent protein in mononuclear phagocytes (MPs). The hosts were challenged with Escherichia coli (E.coli) expressing the ovalbumin protein (OVA) fused to a cyan fluorescent protein (CFP).
02:42
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
0 Views •
2025
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor cells.
FAQs
Following vaccination, antigen-presenting cells process the delivered tumor-related material and present relevant molecular targets to the adaptive immune system. This activates antigen-specific T cells, which can recognize cancer cells displaying the corresponding antigen and contribute to their destruction. The effectiveness of this sequence depends on generating a sufficiently focused immune response against cells that carry the selected target.
Tumor-associated antigens are targets displayed by cancer cells but may also occur in other contexts, whereas tumor-specific antigens are more closely linked to the cancer itself. This distinction influences how selectively the immune response can focus on malignant cells. In cancer research, comparing these antigen categories helps guide target selection for vaccine design and personalized treatment strategies.
The formulation determines how tumor-derived targets are delivered to the immune system. Peptides, proteins, genetic material, or tumor-derived components can serve as vaccine materials, while adjuvants strengthen immune activation. Together, these choices influence antigen presentation and the development of antigen-specific T-cell responses, making formulation an important variable when studying or optimizing tumor immunity.
The sequence begins when the vaccine supplies tumor-related molecular targets, sometimes together with an adjuvant. Antigen-presenting cells then process those targets and initiate adaptive immune activation. Antigen-specific T cells are subsequently generated or stimulated, enabling them to identify cells displaying the corresponding antigen. This workflow provides a framework for examining how vaccination shapes antitumor immunity.
These vaccines may be studied for preventing cancer recurrence, controlling established disease, or improving responses to other immunotherapies. Their use therefore extends beyond examining whether vaccination can stimulate immunity in isolation. Researchers can evaluate how antigen-specific immune responses relate to different treatment goals and whether vaccination has value within broader, combined immunotherapy strategies.
Personalized strategies can focus vaccine development on tumor antigens relevant to an individual cancer, rather than treating every tumor as immunologically identical. Studying which antigens are displayed and how strongly immune cells respond helps connect molecular tumor features with treatment design. This approach makes tumor antigen vaccines useful for investigating patient-specific immune recognition and therapeutic planning.